Results 11 to 20 of about 21,053 (285)

Anticoagulation with Edoxaban in Patients with Atrial High-Rate Episodes

New England Journal of Medicine, 2023
BACKGROUND Device-detected atrial high-rate episodes (AHREs) are atrial arrhythmias detected by implanted cardiac devices. AHREs resemble atrial fibrillation but are rare and brief. Whether the occurrence of AHREs in patients without atrial fibrillation (
Martin Borlich
exaly   +2 more sources

Edoxaban versus Warfarin in Patients with Atrial Fibrillation

New England Journal of Medicine, 2013
BACKGROUND Edoxaban is a direct oral factor Xa inhibitor with proven antithrombotic effects. The long-term efficacy and safety of edoxaban as compared with warfarin in patients with atrial fibrillation is not known.
Robert P Giugliano, Eugene Braunwald, Michael D Ezekowitz   +2 more
exaly   +2 more sources

Effectiveness of edoxaban in portal vein thrombosis associated with liver cirrhosis

Scientific Reports
Portal vein thrombosis (PVT) worsens the long-term prognosis of patients with cirrhosis; however, the optimal treatment remains to be determined. Reports on the efficacy of direct oral anticoagulants are increasing, and further evidence is needed ...
Tomoko Tadokoro, Joji Tani, Takushi Manabe, Kei Takuma, Mai Nakahara, Kyoko Oura, Shima Mimura, Koji Fujita, Takako Nomura, Asahiro Morishita, Hideki Kobara, Takashi Himoto, Masafumi Ono, Tsutomu Masaki   +13 more
doaj   +2 more sources

Clinical trial assessing the safety of edoxaban with concomitant chemotherapy in patients with gynecological cancer-associated thrombosis (EGCAT study)

Thrombosis Journal, 2023
Background Gynecological cancer is one of the highest risk factors for cancer-associated thrombosis (CAT). Although low-molecular-weight heparin (LMWH) is recommended as an anticoagulant for treating CAT, recent studies have shown that direct oral ...
Tadashi Oride, Kenjiro Sawada, Aasa Shimizu, Yasuto Kinose, Tsuyoshi Takiuchi, Michiko Kodama, Kae Hashimoto, Eiji Kobayashi, Eiji Nakatani, Tadashi Kimura   +9 more
doaj   +2 more sources

Edoxaban: An Update on the New Oral Direct Factor Xa Inhibitor [PDF]

Drugs, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Henri Bounameaux, Alan J Camm
exaly   +3 more sources

Efficacy and Safety of Renal Function on Edoxaban Versus Warfarin for Atrial Fibrillation: A Systematic Review and Meta-Analysis

Medicines, 2023
Background: Edoxaban is a novel oral anticoagulant which may decrease the risk of stroke and systemic embolism in patients suffering from atrial fibrillation (AF).
Yapeng Wang, Li Li, Zhanlan Wei, Shan Lu, Wenxue Liu, Janghui Zhang, Junbo Feng, Dongjin Wang   +7 more
doaj   +2 more sources

Prolonged Secondary Stroke Prevention with Edoxaban: A Long-Term Follow-Up of the SATES Study

Brain Sciences, 2023
Background: Little evidence is available on the long-term efficacy and safety of edoxaban, mainly due to the recent release date. The primary objective of the study was to evaluate the safety of edoxaban, defined by the incidence of major bleedings.
Irene Scala, Simone Bellavia, Pier Andrea Rizzo, Jacopo Di Giovanni, Mauro Monforte, Roberta Morosetti, Giacomo Della Marca, Fabio Pilato, Aldobrando Broccolini, Paolo Profice, Giovanni Frisullo   +10 more
doaj   +2 more sources

An evidence-based review of edoxaban and its role in stroke prevention in patients with nonvalvular atrial fibrillation [PDF]

, 2015
Atrial fibrillation is the most common arrhythmia in the elderly. It is responsible for significant morbidity and mortality from cardioembolic complications like stroke.
Prakash Deedwania, Tushar Acharya
openalex   +4 more sources

Physiologically‐based pharmacokinetic pharmacodynamic parent‐metabolite model of edoxaban to predict drug–drug‐disease interactions: M4 contribution

CPT: Pharmacometrics & Systems Pharmacology, 2023
This study aimed to develop a physiologically‐based pharmacokinetic pharmacodynamic (PBPK/PD) parent‐metabolite model of edoxaban, an oral anticoagulant with a narrow therapeutic index, and to predict pharmacokinetic (PK)/PD profiles and potential drug ...
Ruijuan Xu, Wenyuan Liu, Weihong Ge, Hua He, Qing Jiang   +4 more
doaj   +2 more sources

Low-Dose Edoxaban in Very Elderly Patients with Atrial Fibrillation

New England Journal of Medicine, 2020
BACKGROUND Implementation of appropriate oral anticoagulant treatment for the prevention of stroke in very elderly patients with atrial fibrillation is challenging because of concerns regarding bleeding.
Masaharu Akao, Tetsuro Yoshida, Masayuki Fukuzawa   +2 more
exaly   +2 more sources